The company’s new version of its glycan analysis tool will help investigators determine the relative abundance of individual N-glycan structures in small biopharmaceutical samples.
Although Waters officially introduced its GlycoWorks RapiFluor-MS N-Glycan Kit in January 2015, the company announced on Dec. 16, 2015 that it has now released a version of the tool for smaller sample volumes. The release was coordinated in response to industry feedback, and is meant for companies that wanted to harness the tool’s deglycosylation and labeling features but could not invest in the larger, 96-sample format.
The new tool can accommodate 24 samples rather then 96 samples, so companies can incorporate the tool to perform routine biotherapeutic glycan analysis for smaller samples. According to the company, use of the kit allows for analysis “with greater speed, accuracy, and consistency than by using disparate instruments and processes.”
A Waters representative said that the biopharmaceutical company Regeneron, which is based in Tarrytown, NY, has already adopted the new RapiFluor-based workflow for the enzymatic deglycosylation of early-phase monoclonal antibodies (mAbs). Regeneron said that its use of the tool reduced sample prep time significantly, reducing the total prep time from a range 6–24 hours to 45 minutes.
Source: Waters
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.